Cargando…

The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants

PURPOSE: Roux-en-Y gastric bypass (RYGB) involves alterations of the gastrointestinal tract resulting in altered absorption. Patients with obesity have a higher prevalence of depression, and antidepressants are often prescribed. Alterations caused by RYGB could modify drug bioavailability and cause...

Descripción completa

Detalles Bibliográficos
Autores principales: Garin, Paul, Favre, Lucie, Vionnet, Nathalie, Frantz, Johanna, Eap, Chin B., Vandenberghe, Frederik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156620/
https://www.ncbi.nlm.nih.gov/pubmed/36949223
http://dx.doi.org/10.1007/s11695-023-06526-1
_version_ 1785036576161529856
author Garin, Paul
Favre, Lucie
Vionnet, Nathalie
Frantz, Johanna
Eap, Chin B.
Vandenberghe, Frederik
author_facet Garin, Paul
Favre, Lucie
Vionnet, Nathalie
Frantz, Johanna
Eap, Chin B.
Vandenberghe, Frederik
author_sort Garin, Paul
collection PubMed
description PURPOSE: Roux-en-Y gastric bypass (RYGB) involves alterations of the gastrointestinal tract resulting in altered absorption. Patients with obesity have a higher prevalence of depression, and antidepressants are often prescribed. Alterations caused by RYGB could modify drug bioavailability and cause potential subtherapeutic plasma concentrations, increasing the risk of depressive relapse. The aim of this study was to describe the evolution of trough drug dose-normalized antidepressant plasma concentrations before and after RYGB. MATERIALS AND METHODS: This naturalistic prospective case series considers patients with trough plasma concentrations in a 1-year timeframe before and after RYGB. Only antidepressants prescribed to at least three patients were included in the present study. RESULTS: Thirteen patients (n = 12 females, median age 44 years, median BMI before intervention = 41.3 kg/m(2)) were included. Two patients were treated concurrently with fluoxetine and trazodone; the remaining patients were all treated with antidepressant monotherapy. Therapeutic drug monitoring (TDM) values for duloxetine (n = 3), escitalopram (n = 4), fluoxetine (n = 4), and trazodone (n = 4) before (median 4.7 weeks) and after (median 21.3 weeks) RYGB intervention were analyzed. Compared to preintervention, median [interquartile range] decreases in dose-normalized trough plasma concentrations for duloxetine (33% [− 47; − 23]), escitalopram (43% [− 51; − 31]), fluoxetine (9% [− 20; 0.2]), and trazodone (16% [− 29; 0.3]) were observed. CONCLUSION: This study shows a decrease in plasma antidepressant concentrations following RYGB. TDM before and after RYGB, in addition to close monitoring of psychiatric symptomatology, may help optimize antidepressant treatment after bariatric surgery. These results also highlight the need for prospective studies assessing the clinical evidence available through TDM in these patients. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-10156620
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-101566202023-05-05 The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants Garin, Paul Favre, Lucie Vionnet, Nathalie Frantz, Johanna Eap, Chin B. Vandenberghe, Frederik Obes Surg Original Contributions PURPOSE: Roux-en-Y gastric bypass (RYGB) involves alterations of the gastrointestinal tract resulting in altered absorption. Patients with obesity have a higher prevalence of depression, and antidepressants are often prescribed. Alterations caused by RYGB could modify drug bioavailability and cause potential subtherapeutic plasma concentrations, increasing the risk of depressive relapse. The aim of this study was to describe the evolution of trough drug dose-normalized antidepressant plasma concentrations before and after RYGB. MATERIALS AND METHODS: This naturalistic prospective case series considers patients with trough plasma concentrations in a 1-year timeframe before and after RYGB. Only antidepressants prescribed to at least three patients were included in the present study. RESULTS: Thirteen patients (n = 12 females, median age 44 years, median BMI before intervention = 41.3 kg/m(2)) were included. Two patients were treated concurrently with fluoxetine and trazodone; the remaining patients were all treated with antidepressant monotherapy. Therapeutic drug monitoring (TDM) values for duloxetine (n = 3), escitalopram (n = 4), fluoxetine (n = 4), and trazodone (n = 4) before (median 4.7 weeks) and after (median 21.3 weeks) RYGB intervention were analyzed. Compared to preintervention, median [interquartile range] decreases in dose-normalized trough plasma concentrations for duloxetine (33% [− 47; − 23]), escitalopram (43% [− 51; − 31]), fluoxetine (9% [− 20; 0.2]), and trazodone (16% [− 29; 0.3]) were observed. CONCLUSION: This study shows a decrease in plasma antidepressant concentrations following RYGB. TDM before and after RYGB, in addition to close monitoring of psychiatric symptomatology, may help optimize antidepressant treatment after bariatric surgery. These results also highlight the need for prospective studies assessing the clinical evidence available through TDM in these patients. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2023-03-22 2023 /pmc/articles/PMC10156620/ /pubmed/36949223 http://dx.doi.org/10.1007/s11695-023-06526-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Contributions
Garin, Paul
Favre, Lucie
Vionnet, Nathalie
Frantz, Johanna
Eap, Chin B.
Vandenberghe, Frederik
The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants
title The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants
title_full The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants
title_fullStr The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants
title_full_unstemmed The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants
title_short The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants
title_sort influence of a roux-en-y gastric bypass on plasma concentrations of antidepressants
topic Original Contributions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156620/
https://www.ncbi.nlm.nih.gov/pubmed/36949223
http://dx.doi.org/10.1007/s11695-023-06526-1
work_keys_str_mv AT garinpaul theinfluenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants
AT favrelucie theinfluenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants
AT vionnetnathalie theinfluenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants
AT frantzjohanna theinfluenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants
AT eapchinb theinfluenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants
AT vandenberghefrederik theinfluenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants
AT garinpaul influenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants
AT favrelucie influenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants
AT vionnetnathalie influenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants
AT frantzjohanna influenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants
AT eapchinb influenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants
AT vandenberghefrederik influenceofarouxenygastricbypassonplasmaconcentrationsofantidepressants